GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
X

XORTX Therapeutics XRTX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.85

-7.14%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$2.7m

FY2015FY2025

Free cash flow

−$2.8m

FY2015FY2025

Shareholders' equity

$2.1m

FY2015FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2016FY2015
Research and development$574,935$183,830$2.4m$6.5m$853,124$277,455$39,897$245,044——
Operating income−$3.3m−$4.1m−$6.0m−$9.9m−$3.6m−$1.3m−$565,965−$828,544−$389,315−$243,935
Net income−$2.7m−$3.3m−$2.2m−$7.0m−$1.7m−$1.3m−$629,576−$2.7m−$414,834−$279,309
Diluted earnings per share-2.02-25.04-26.98-109.89-30.15-41.71-26.45-113.59-70.31-34.48

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2016FY2015
Total assets$2.7m$4.1m$5.5m$12.3m$22.0m$2.3m$1.1m$905,885$282,463$203,435
Cash and short-term investments————————$166,491$27,013
Total liabilities$599,071$757,990$825,938$5.4m$5.3m$1.0m$1.3m$675,671$599,525$6,166
Debt———————$30,970$124,127—
Shareholders' equity$2.1m$3.3m$4.6m$7.0m$16.7m$1.3m−$211,721$230,214−$317,062$197,269
Shares outstanding1m0m0m0m0m0m0m0m0m—

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2016FY2015
Cash from operations−$2.8m−$3.7m−$6.6m−$12.0m−$6.1m−$728,401−$249,580−$1.1m−$107,784−$128,574
Capital spending−$55,223−$38,924−$46,363−$25,779−$25,779−$25,779−$25,779−$29,407−$3,790−$39,111
Free cash flow−$2.8m−$3.7m−$6.6m−$12.0m−$6.1m−$754,180−$275,359−$1.1m−$111,574−$167,685

Latest quarters

By quarter end

Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024
Operating income−$823,297−$686,416−$716,197−$889,945−$963,456−$661,264−$874,749−$1.5m
Net income−$808,472−$590,462−$649,469−$717,700−$698,673$122,535−$587,011$170,066
Diluted earnings per share-0.50-0.45-0.49-0.55-0.530.93-4.441.29
Total assets$2.1m$2.7m$2.8m$2.7m$3.5m$4.1m$3.9m$4.8m
Shareholders' equity$1.3m$2.1m$2.0m$2.0m$2.7m$3.3m$2.1m$2.7m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-30.9%20.1%29.6%
Net income-27.6%15.6%25.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-1.4-0.2-0.4-3.0-27.5

Share price return

Finished calendar years

20252024202320222021
Return-47%-55%-96%-61%-61%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 5-to-1 reverse split · 6 Apr 2026

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.